5,244
edits
Non-Hodgkin lymphoma: Difference between revisions
no edit summary
(Created page with "'''Non-Hodgkin lymphomas''' (NHLs) are a heterogenous group of lymphomas. We distinguish indolent/low-grade NHLs, aggressive/high-grade NHLs, and intermediary NHLs. The indolent/low-grade non-Hodgkin lymphomas are much less harmful than the aggressive/high-grade ones. In many cases, patients die ''with'' indolent lymphomas rather than ''of'' them. They remain asymptomatic for many years and are therefore often diagnosed incidentally on a laboratory test rat...") |
No edit summary |
||
| Line 62: | Line 62: | ||
The R-CHOP regimen involves rituximab, cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin®), and prednisone. Rituximab is an anti-CD20 antibody and is only given if the disease is CD20+. | The R-CHOP regimen involves rituximab, cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin®), and prednisone. Rituximab is an anti-CD20 antibody and is only given if the disease is CD20+. | ||
[[Category:Haematology]] | [[Category:Haematology]] | ||
[[Category:Internal Medicine (POTE course)]] | |||